Akoya Q1 revenue falls 14% to $18.4M; cuts FY2024 revenue guidance to $104-$112M

Akoya Biosciences, Inc.

2024-Q1 EPS reported -$0.48 revenue$18,350,000

Revenue $18.4M, down 14% YoY; GAAP operating loss $21.6M (non-GAAP $15.2M).
GAAP gross margin 46% (57% non-GAAP adjusted) from legacy instrument write-off.
Installed base up 22% to 1,213; 1,307 publications +52% YoY.
Cash $61.6M; reaffirms target of operating cash flow breakeven by year-end 2024.
Cites capex pressure, deferred pharma lab revenue, and reagent fulfillment delays.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Akoya Biosciences, Inc. reported the first quarter ending March 31, 2024 results: revenue $18.4 million. Guidance lowered.

Period: the first quarter ending March 31, 2024
Revenue: $18.4 million
Guidance: lowered
Result: reported results

Exact text from the filing

(Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024. Business Highlights ● Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase. ● Akoya announced the

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001558370-24-007957

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.